Grade 3–4 osimertinib-induced interstitial lung disease in epidermal growth factor receptor-mutated non-small cell lung cancer significantly reduced survival compared to lower grades, with substantial interstitial lung disease recurrence risk upon subsequent therapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.